PALI - palisadebio.com Debt to Book Capitalization Ratio
The debt-to-balance sheet capitalization ratio visualizes the financial leverage of Palisade Bio, Inc. (PALI), where the value 0.00 reflects current dynamics. Palisade Bio, Inc. (PALI) is developing a line of protease inhibitors to capture the gastrointestinal therapy segment. Patent protection for tissue regeneration methods and stringent regulatory oversight create significant barriers to entry. Meanwhile, engaging external CRO partners for trials does not limit control over intellectual property.
%20Debt%20to%20Net%20Assets%20Ratio&width=1200&height=400&colorIndex=0&v=mvq8bmkb.8d-7aozthc&start=20220704&end=20261027&filename=GURU_Markets_-_PALI_-_Palisade-Bio-Inc._-_Debt-to-Net-Assets-Ratio "Palisade Bio - PALI Debt to Book Capitalization Ratio (period 07/04/2022 - 10/27/2026) | 👁️GURU.Markets👁️")
Metric breakdowns and analytics for palisadebio.com (PALI)
The specifics of Palisade Bio, Inc. (PALI) within a narrow medical segment necessitate significant expenditures for patent commercialization. This metric compares total liabilities to total book capital to determine the business's degree of dependence on borrowed funds. The current "debt / book capitalization" structure illustrates the stability of the financial leverage. An increase in this indicator signals heightened risks given the limited scale of capital, which is critical for assessing the company's solvency.